Chemoprevention of Prostate Cancer

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 831-843

  Brand, Timothy C ^a   Canby Hagino, Edith D ^a   Pratap Kumar, A ^a   Ghosh, Rita ^a   Leach, Robin J ^a   Thompson, Ian M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ALPHA TOCOPHEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; FINASTERIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PYRIDOXINE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SELENOMETHIONINE; STEROID 5ALPHA REDUCTASE INHIBITOR; TOREMIFENE;

AGE DISTRIBUTION; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CPG ISLAND; DIET THERAPY; DNA DAMAGE; DNA POLYMORPHISM; DRUG SAFETY; EPIGENETICS; ETHNOLOGY; FAMILY HISTORY; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GLEASON SCORE; HEREDITY; HUMAN; INFLAMMATION; ISOPRENYLATION; LIFE EXPECTANCY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SEX ROLE; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33746029437     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.03.012     Document Type: Review

References (77)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
2. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 15 (1998) 1036-1042
3. McDavid K., Lee J., Fulton J.P., et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119 2 (2004) 174-186
4. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 19 (2005) 1407-1427
5. Surveillance Epidemiology and End Results. US National Institute of Health; 2005. Available at: www.seer.cancer.gov. Accessed August 15, 2005.
6. Bruner D.W., Moore D., Parlanti A., et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 107 5 (2003) 797-803
7. Johns L.E., and Houlston R.S. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91 9 (2003) 789-794
8. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 2 (2000) 78-85
9. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155 6 (1999) 1985-1992
10. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 4 (2003) 366-381
11. Nakayama M., Gonzalgo M.L., Yegnasubramanian S., et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 91 3 (2004) 540-552
12. Bastian P.J., Palapattu G.S., Lin X., et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11 11 (2005) 4037-4043
13. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 2 (1996) 159-170
14. Gelmann E.P., Steadman D.J., Ma J., et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Res 62 9 (2002) 2654-2659
15. Cairns P., Okami K., Halachmi S., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57 22 (1997) 4997-5000
16. Zhao H., Dupont J., Yakar S., et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23 3 (2004) 786-794
17. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168 1 (2002) 9-12
18. Cicek M.S., Conti D.V., Curran A., et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59 1 (2004) 69-76
19. Forrest M.S., Edwards S.M., Houlston R., et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8 1 (2005) 95-102
20. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75 4 (1992) 1022-1026
21. Wilson J.D., and Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab 84 12 (1999) 4324-4331
22. Zegarra-Moro O.L., Schmidt L.J., Huang H., et al. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62 4 (2002) 1008-1013
23. Gnanapragasam V.J., Robson C.N., Leung H.Y., et al. Androgen receptor signalling in the prostate. BJU Int 86 9 (2000) 1001-1013
24. Balic I., Graham S.T., Troyer D.A., et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 168 5 (2002) 2245-2248
25. Zeegers M.P., Kiemeney L.A., Nieder A.M., et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol Biomarkers Prev 13 11 Pt 1 (2004) 1765-1771
26. Visvanathan K., Helzlsouer K.J., Boorman D.W., et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 171 2 Pt 1 (2004) 652-655
27. Ma J., Stampfer M.J., Gann P.H., et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7 5 (1998) 385-390
28. Gsur A., Feik E., and Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 21 6 (2004) 414-423
29. Verhage B.A.J., and Kiemeney L.A.L.M. Inherited predisposition to prostate cancer. Eur J Epidemiol 18 11 (2003) 1027-1036
30. Chen J.Z., and Kadlubar F.F. Mitochondrial mutagenesis and oxidative stress in human prostate cancer. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 22 1 (2004) 1-12
31. Heber D., and Lu Q.Y. Overview of mechanisms of action of lycopene. Exp Biol Med 227 10 (2002) 920-923
32. Li N., Oberley T.D., Oberley L.W., et al. Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35 3 (1998) 221-233
33. Zhong W., and Oberley T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61 19 (2001) 7071-7078
34. Klein E.A. Selenium: epidemiology and basic science. J Urol 171 2 Pt 2 (2004) S50-S53 [discussion S53]
35. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54 2 (1996) 83-94
36. Lucia M.S., and Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171 2 Pt 2 (2004) S30-S34 [discussion S35]
37. Basler J.W., and Piazza G.A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171 2 Pt 2 (2004) S59-S62 [discussion S62-53]
38. Palapattu G.S., Sutcliffe S., Bastian P.J., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 7 (2005) 1170-1181
39. Amling C.L. Relationship between obesity and prostate cancer. Curr Opin Urol 15 3 (2005) 167-171
40. Bergstrom A., Pisani P., Tenet V., et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91 3 (2001) 421-430
41. Porter M.P., and Stanford J.L. Obesity and the risk of prostate cancer. Prostate 62 4 (2005) 316-321
42. Freedland S.J., Isaacs W.B., Mangold L.A., et al. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 11 8 (2005) 2883-2888
43. Rodriguez C., Patel A.V., Calle E.E., et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10 4 (2001) 345-353
44. Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58 3 (2001) 411-416
45. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 3 (2003) 215-224
46. Zeliadt S.B., Etzioni R.D., Penson D.F., et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 118 8 (2005) 850-857
47. Lotan Y., Cadeddu J.A., Lee J.J., et al. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23 9 (2005) 1911-1920
48. Unger J.M., LeBlanc M., Thompson I.M., et al. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol 22 4 (2004) 362-368
49. Schwartz K.L., Grignon D.J., Sakr W.A., et al. Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology 53 4 (1999) 769-774
50. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 22 (2004) 2239-2246
51. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 1 (2005) 66-70
52. Bramson H.N., Hermann D., Batchelor K.W., et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282 3 (1997) 1496-1502
53. Clark R.V., Hermann D.J., Cunningham G.R., et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89 5 (2004) 2179-2184
54. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 4 Pt 1 (2004) 1314-1317
55. Traber M.G., and Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr 62 6 Suppl (1995) 1501S-1509S
56. Mahoney C.W., and Azzi A. Vitamin E inhibits protein kinase C activity. Biochem Biophys Res Commun 154 2 (1988) 694-697
57. Klein E.A., Thompson I.M., Lippman S.M., et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 166 4 (2001) 1311-1315
58. Heinonen O.P., Albanes D., Virtamo J., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90 6 (1998) 440-446
59. Recommended Dietary Allowances. 10th edition (1989), National Academy Press, Washington, DC
60. Clark L.C., Combs Jr. G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 24 (1996) 1957-1963
61. Lippman S.M., Goodman P.J., Klein E.A., et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97 2 (2005) 94-102
62. Waddell W.R., and Loughry R.W. Sulindac for polyposis of the colon. J Surg Oncol 24 1 (1983) 83-87
63. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 26 (2000) 1946-1952
64. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 9 (2001) 4261-4267
65. Andrews J., Djakiew D., Krygier S., et al. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 50 4 (2002) 277-284
66. Harris R.E., Beebe-Donk J., Doss H., et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13 4 (2005) 559-583
67. Platz E.A., Rohrmann S., Pearson J.D., et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14 2 (2005) 390-396
68. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 11 (2005) 1092-1102
69. Newton C.J., Ran G., Xie Y.X., et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 174 1 (2002) 7-16
70. Perez-Sala D., and Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199 3 (1994) 1209-1215
71. Graaf M.R., Beiderbeck A.B., Egberts A.C., et al. The risk of cancer in users of statins. J Clin Oncol 22 12 (2004) 2388-2394
72. Cyrus-David M.S., Weinberg A., Thompson T., et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173 6 (2005) 1923-1925
73. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 22 6 (2004) 472-477
74. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 22 6 (2004) 466-471
75. Steiner M.S., Raghow S., and Neubauer B.L. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology 57 4 Suppl 1 (2001) 68-72
76. Severson R.K., Nomura A.M., Grove J.S., et al. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49 7 (1989) 1857-1860
77. Santibanez J.F., Navarro A., and Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 17 2A (1997) 1199-1204